Qisda, a leading system integration company, announced on the 15th that it would participate in Sunhawk Vision Biotech’s private placement. The company will subscribe to 4,000 common shares at a price of NT$54 per share, totaling NT$216 million, resulting in a 5.71% equity stake. Qisda emphasized that this investment will strengthen collaboration between the two companies in the ophthalmology sector of the medical industry. Leveraging Qisda Healthcare Group’s distribution network, the partnership aims to unlock greater business opportunities and create a win-win scenario.
The subscription price for this investment was determined based on the pricing of Sunhawk Vision Biotech’s private placement common shares and a fairness opinion issued by an independent accountant. The net value of each share acquired is NT$4.71. The funds for this transaction come from Qisda’s internal resources. According to the company’s disclosure, investments in private placement securities (including this transaction) account for 4.08% of Qisda’s total assets as per the latest financial statements, and 11.24% of equity attributable to the parent company’s shareholders.
Qisda has a strong foundation in medical technology and has actively showcased its achievements in integrating smart healthcare with AI applications in recent years. Chairman Peter Chen recently stated that the performance of its healthcare businesses remains optimistic, with quarterly revenues consistently around NT$6 billion. The company continues to see growth across its hospital, medical device, and pharmaceutical distribution sectors. In addition to accelerating hospital growth by advancing BenQ BM Holding Cayman Corp's entry into the capital market, the board recently approved a public acquisition to increase its stake in NORBEL BABY (formerly Ding Ding Pharmacy), further strengthening its position in the medical retail distribution market.
General Manager HanChou Huang also commented that Qisda’s IT business continues to grow steadily. The commercial and industrial markets, as well as the networking and communication sectors, which were previously impacted by client inventory adjustments, have now shown signs of stabilization. Looking ahead, the group will continue to focus on streamlining its core businesses while investing in new ventures. By collaborating with suppliers, Qisda aims to co-create a resilient and sustainable value chain to address ongoing challenges posed by climate change and market dynamics.
Resource: 佳世達斥資2.16億元 以每股54元參與視航生醫私募
